European private equity firm, Cinven, today announces the acquisition of the Amdipharm Group ("Amdipharm" or "the Group"), the family-owned international niche pharmaceuticals business, for a total consideration of £367 million.
Amdipharm will operate initially as a standalone business but, over time, Cinven will look to merge Amdipharm with its existing portfolio company, Mercury Pharma, which it acquired in September 2012. The combination demonstrates the execution of Cinven's consolidation strategy within the niche pharmaceuticals sector.
Mercury and Amdipharm each market mature, niche pharmaceuticals, both branded and unbranded. The businesses are highly complementary as Mercury's customer base is largely UK focused, whereas Amdipharm has a significantly greater international business, with its products sold in over 80 countries worldwide.
The Group, which has grown strongly through acquisition, today generates revenues of over £110 million.